

ASX ANNOUNCEMENT

30 January 2024

## **ENTITLEMENT OFFER CLOSING & DEADLINE FOR APPLICATIONS**

Highlights:

- \$4 million Entitlement Offer will close at 5:00pm (AEDT) on Thursday, 1 February 2024.
- \$4.3 million 31 December 2023 cash balance.
- Cash balance to increase with Institutional Placement and Entitlement Offer proceeds.

CardieX Limited (ASX: CDX) (**CardieX**, the **Company**) would like to remind interested eligible shareholders that, unless extended, the Entitlement Offer announced on 19 December 2023 will close at 5:00pm (AEDT) on Thursday, 1 February 2024. Application monies are due by this time.

The Entitlement Offer provides eligible shareholders the opportunity to acquire new CardieX shares at the same price of \$0.08 per share as the Company's recent Institutional Placement (refer to ASX announcement dated 19 December 2023).

Completion of the Institutional Placement is subject to shareholder approval at an Extraordinary General Meeting being held on 1 February 2024.

The Company lodged a Prospectus for the Entitlement Offer with ASIC and the ASX on 19 December 2023 and an application form has been mailed to eligible shareholders. Eligible shareholders are to refer to their personalised application form for further details.

## Commenting on the Entitlement Offer opportunity, CEO Craig Cooper said:

The Entitlement Offer to shareholders completes a significant fundraising package for the Company that already includes a commitment of \$4m in the Institutional Placement, and \$7.5m from directors Niall Cairns and myself through C2 Ventures (C2V). Together with a successful completion of the Entitlement Offer this funding package places the Company in a strong position to launch its new suite of vascular biomarker technologies in the US & global healthcare market and puts the Company on a path to reach and sustain profitability in the coming years.

The Entitlement Offer is priced at the same level as the Placement that has already been fully committed to by new and existing institutions, family offices, and some existing large shareholders.

For further information on the Company's corporate and business activities I would encourage shareholders to review the Company's investment webinar presentation released to the ASX on January 18 and our latest Quarterly Update released to the ASX today.

Any shareholder requiring assistance with their application are encouraged to call Louisa Ho, CardieX Company Secretary, during business hours, on +61 2 9713 9495. Shareholders can also email <u>contact@cardiex.com</u>.

## Approved by the Board of Directors and Released by the Company Secretary

For more information, please contact:

Investor Relations Rod Hinchcliffe rod.hinchcliffe@mcpartners.com.au

Media Relations Melissa Hamilton melissa.hamilton@mcpartners.com.au

Investor Relations – USA Matt Selinger Managing Director, Integrous Communications mselinger@integcom.com

## About CardieX

CardieX is a medical technology company that develops and markets non-invasive patient monitoring technologies for assessing vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor<sup>®</sup> vascular biomarker technology. CardieX is listed on the Australian Stock Exchange ("CDX").